2022
- ALA-1000 Received notice of patent allowance from National Institute of Industrial Property Institute (INAPI), Chile on August 10, Application No. 624-2019
- ALA-1000 Received notice of patent allowance from European Patent Office (EPO) on May 12 , Application No. 17850245.6.
- ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI on May 12, Application No. 000487-2019/DIN .
- Alar-1000 Received notice of patent allowance from Intellectual Property Office of India on May 6, Application No. 201947006642.
- Alar-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS) on April 21, Application No. 11201901294Q.
- Alar Announces Significant Progress on Developing long-acting Buprenorphine
Injectable ALA-1000 on January 13.
2021
- Alar-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia on November 30 , Application No. P00201902139.
- Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients on November 09.
- ALA-1000 Received notice of patent allowance from Intellectual Property Office of Vietnam on October 29, Application No. 1-2019-01258.
- Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder on October 28.
- ALA-1000 Receive notice of patent allowance from Taiwan Intellectual Property Office (TIPO) on September 3, Application No. 106131215.
- ALA-1000 Receive notice of patent allowance from South Africa-Companies and Intellectual Property Commission Department of Trade and Industry (CIPC) on August 25, Application No. 2019/00890.
- ALA-1000 Receive notice of patent allowance from Japan Patent Office (JPO) on August 3, Application No. 特願2019-535434.
- ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED) on May 10, 2021, Application No.3,033,046.
- ALA-1000 Receive notice of patent allowance from the IP New Zealand on April 30, 2021. Patent No. 750367
- ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office on April 16, 2021 (Application No. 10-2019-7009185).
- ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) on April 12, 2021 (Application No. 2019102895).
2020
- Listed on Taipei Exchange Market in Taiwan on 23 September ，Traded on October 5
- ALA-1000 Receive notice of patent allowance from the IP Australia.
- ALA-3000 completes Pre-IND Meeting with US FDA
- ALA-1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI)
- Approved to be a public offering company on June 3. Code : ( 6785 )
- Receive notice of patent allowance from USPTO ( ALA-1000)
- ALA-1000 was approved by Ministry of Economic Affairs : A+ Industrial Innovation R&D Program(fast track)
2019
Approved by the Ministry of Economic Affairs as a Biotech Pharmaceutical company
ALA-1000 received US FDA IND approval.
Approved to locate in Central Science Park
2017
- ALA-1000 was approved by Ministry of Economic Affairs ：A+ Industrial Innovation R&D Program－Industrial Technology Foresight Research Program
2016
- Alar Pharmaceuticals Inc was founded